Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

DARA's DB959 shows promise against type 2 diabetes

A new peroxisome proliferator activated receptor agonist currently in development, DB959, will most likely be administered orally once a day, according to a presentation made by researchers recently at the American Diabetes Association's 71st Scientific Sessions.

14 Jul 2011

U.S. Senators introduce Pulmonary Fibrosis Research Enhancement Act

The Coalition for Pulmonary Fibrosis (CPF) announced today the Pulmonary Fibrosis Research Enhancement Act has been introduced in the Senate by Senators Chris Coons and Mike Crapo in the U.S. House of Representatives by Rep. Erik Paulsen and Rep. Tammy Baldwin.

13 Jul 2011

MicroOCT technology can reveal cellular features of coronary artery disease

Researchers at the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH) have developed a one-micrometer-resolution version of the intravascular imaging technology optical coherence tomography (OCT) that can reveal cellular and subcellular features of coronary artery disease.

11 Jul 2011

AJMS summarizes developments related to idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a common and severe lung disease of unknown cause and with no proven therapies. But researchers are pushing forward in investigating new clues to the development and effective treatment of IPF, according to a special symposium presented in The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation (SSCI).

8 Jul 2011

Enrollment commences in InterMune's Esbriet Phase 3 study for IPF

InterMune today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis.

8 Jul 2011

Nanoscientist to develop new microsystem for more efficient drug-testing

A University of Southampton nanoscientist is working on a new microsystem for more efficient testing of pharmaceutical drugs to treat diseases such as cystic fibrosis, MG (myasthenia gravis) and epilepsy.

6 Jul 2011

Study confirms link between delayed access to tertiary care for IPF, higher risk of death

Idiopathic pulmonary fibrosis (IPF)―scarring and thickening of the lungs from unknown causes―is the predominant condition leading to lung transplantation nationwide. Columbia University Medical Center researchers confirmed that delayed access to a tertiary care center for IPF is associated with a higher risk of death.

2 Jul 2011

Small molecule treatment holds promise for Usher syndrome

New treatment approach shall soon be ready for use in Usher syndrome patients / Publication in "Human Gene Therapy".

1 Jul 2011

Gene PNPLA3 offers potential therapeutic target in chronic hepatitis C liver damage

New research confirms that a variant on the patatin-like phospholipase-3 (PNPLA3) gene increases risk of steatosis and fibrosis progression in patients with chronic hepatitis C virus (HCV). The PNPLA3 single nucleotide polymorphism (SNP) rs 738409 may represent an important genetic predictor and potential therapeutic target in chronic HCV liver damage.

29 Jun 2011

Researchers identify new lung stem cell that helps repair large airways

Researchers at UCLA have identified a new stem cell that participates in the repair of the large airways of the lungs, which play a vital role in protecting the body from infectious agents and toxins in the environment.

28 Jun 2011

Flamel, Digna Biotech enter joint development agreement for multiple products

Flamel Technologies SA and Digna Biotech SL today announced that the two companies have entered into a joint development agreement for the pre-clinical and clinical development of multiple products.

27 Jun 2011

Researchers find potentially dangerous fungus in common household appliances

A potentially pathogenic fungus has found a home living in extreme conditions in some of the most common household appliances, researchers have found. A new paper published in the British Mycological Society journal, Fungal Biology, published by Elsevier, shows that these sites make perfect habitats for extremotolerant fungi.

21 Jun 2011

Breakthrough treatment for Cystic Fibrosis sufferers with 'Celtic Gene'

An international research team led by Queen's University have developed a ground breaking treatment for Cystic Fibrosis sufferers. The new drug will benefit sufferers who have the 'Celtic Gene', a genetic mutation which is particularly common in Ireland.

20 Jun 2011

Pulmatrix introduces novel iSPERSE inhaled dry powder drug delivery platform

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced the launch of iSPERSE, the company's novel inhaled dry powder drug delivery platform.

20 Jun 2011

Ground breaking treatment for Cystic Fibrosis

20 Jun 2011

Miracle cures on the horizon for genetic disease

In a latest break through, scientists have found a new technique to alter the genetic code behind hundreds of diseases and this was hailed by U.S. scientists as a “miracle of modern medicine.” Genes responsible for devastating diseases can be corrected by controlling faulty messenger cells that are central to the body's protein production, researchers said Wednesday.

17 Jun 2011

GenMark prices public offering of common stock

GenMark Diagnostics, Inc., a molecular diagnostics company focused on developing and commercializing proprietary eSensor detection technology, announced today the pricing of a public offering of 7,065,600 shares of its common stock at a price to the public of $4.25 per share.

17 Jun 2011

Pearl advances PT003 dual combination drug candidate into Phase 2 studies for treatment of COPD

Pearl Therapeutics Inc. today announced the advancement of its dual combination product candidate, PT003 and its individual components, PT001 and PT005 into a series of planned Phase 2 studies in patients with moderate-to-severe COPD.

17 Jun 2011

Aradigm demonstrates top line data from ORBIT-1 ARD-3100 Phase 2b study for bronchiectasis

Aradigm Corporation today announced positive top line data from its recently concluded Phase 2b study (Once-Daily Respiratory Bronchiectasis Inhalation Treatment - ORBIT-1) with Aradigm's ciprofloxacin for inhalation (CFI, ARD-3100, LipoquinTM) in patients with non-cystic fibrosis bronchiectasis (BE).

16 Jun 2011

Serious RSV infections may occur in previously healthy infants and children

For most parents, respiratory syncytial virus (RSV) isn't a familiar term. But it's a common cause of serious respiratory infections with a major impact on the health of infants and young children worldwide, according to a special CDC Review Article in the June issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

16 Jun 2011